Luye America Pharmaceuticals Ltd, based in Princeton, NJ, is a subsidiary of Acadia Pharmaceuticals. Acadia is a leading neuroscience company that works tirelessly to develop innovative solutions for individuals facing challenging neurological conditions. Their focus lies in providing crucial treatments for Parkinson's Disease Psychosis and Rett Syndrome.
With a history spanning over 30 years, Acadia has been a pioneer in healthcare, introducing the first FDA-approved therapies for hallucinations and delusions linked to Parkinson's disease psychosis and Rett syndrome. The company's ongoing research targets Prader-Willi syndrome, Alzheimer's disease psychosis, and neuropsychiatric symptoms in CNS disorders.
Committed to addressing unmet medical needs, Acadia Pharmaceuticals is dedicated to improving the quality of life for those affected by neurological disorders. Their mission is driven by a desire to ensure a brighter future for all, embracing diversity, fostering collaboration, and unwaveringly standing by their goal of elevating lives through groundbreaking advancements in neuroscience.
Generated from the website content
